Literature DB >> 6694076

Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography.

Y H Park, M P Kullberg, O N Hinsvark.   

Abstract

A high-performance liquid chromatographic (HPLC) method for the quantitation of dextromethorphan (I) and its three metabolites, dextrorphan (II), 3-hydroxy-9 alpha,13 alpha,14 alpha-morphinan (III), and 3-methoxy-9 alpha,13 alpha,14 alpha-morphinan (IV), in urine was developed. For the analysis of nonconjugated compounds, urine samples at pH 11-11.5, containing 3-methoxy-17-methyl-10-oxo-9 alpha,13 alpha,14 alpha-morphinan as an internal standard, were applied to an extraction column, and the compounds were eluted with 10% n-butyl alcohol-hexane. The organic eluant was extracted with 0.1 M HCl, and an aliquot of the acidic extract was analyzed by HPLC utilizing a 5-micron phenyl column (25 X 0.46-cm i.d.) with a mobile phase of 10 mM potassium phosphate-acetonitrile (45:55, pH 4.0); the column effluent was monitored by UV detection at 280 nm. Free and conjugated metabolites in the enzyme-treated urine were analyzed by selective extraction of I and IV with hexane from urine samples at pH greater than 12 and extraction of II and III with 10% n-butyl alcohol-hexane from urine samples at pH 11-11.5. The minimum quantifiable levels of I-IV ranged from 0.017 to 0.09 micrograms of base/mL and from 0.11 to 0.21 micrograms of base/mL in nonhydrolyzed and hydrolyzed urine, respectively.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6694076     DOI: 10.1002/jps.2600730107

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a French population.

Authors:  J P Frèche; S Dragacci; A M Petit; J P Siest; M M Galteau; G Siest
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.

Authors:  N E Basci; A Bozkurt; S O Kayaalp; A Sayal; A Isimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

3.  Phenotyping polymorphic drug metabolism in the French Caucasian population.

Authors:  E Jacqz; H Dulac; H Mathieu
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study.

Authors:  H-H Sherry Chow; Linda L Garland; Chiu-Hsieh Hsu; Donna R Vining; Wade M Chew; Jessica A Miller; Marjorie Perloff; James A Crowell; David S Alberts
Journal:  Cancer Prev Res (Phila)       Date:  2010-08-17

5.  Oxidative polymorphism of dextromethorphan in a Burundi population.

Authors:  F Nsabiyumva; Y Furet; E Autret; A P Jonville; M Breteau
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.

Authors:  W E Evans; M V Relling; A Rahman; H L McLeod; E P Scott; J S Lin
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

7.  Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.

Authors:  F Broly; C Libersa; M Lhermitte; P Bechtel; B Dupuis
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.